Neoadjuvant PD‐1 Blockade Tislelizumab (BGB‐A317) in Combination With Etoposide and Platinum‐Based Chemotherapy for Limited‐Disease Small Cell Lung Cancer

Shiyue Wan, Shiqi Hu, Yilv Yan, Fenghuan Sun, Dongliang Bian, Jie Luo, Dong Xie, Wenxin He, Liang Duan, Yuming Zhu, Nan Song, Ming Liu, Hongcheng Liu, Gening Jiang, Peng Zhang · 2026

Read Neoadjuvant PD‐1 Blockade Tislelizumab (BGB‐A317) in Combination With Etoposide and Platinum‐Based Chemotherapy for Limited‐Disease Small Cell Lung Cancer by Shiyue Wan, Shiqi Hu, Yilv Yan, Fenghuan Sun, Dongliang Bian, Jie Luo, Dong Xie, Wenxin He, Liang Duan, Yuming Zhu, Nan Song, Ming Liu, Hongcheng Liu, Gening Jiang, Peng Zhang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13542703.txt.

Description

Shiyue Wan and fourteen co-authors report the first trial of immune drug care before surgery for a fast lung cancer. Small cell lung cancer in a limited spread had no such tested plan. Their 2026 trial pairs an immune drug with standard chemo for fifteen patients.

Two thirds of patients saw their tumors shrink. Three fifths reached surgery, and all surgical cuts came out clean at the edges. Deep tumor kill showed in near half the cut cases. Scan reads of sugar use called the deep kill better than size alone. Gene reads showed treated tissue shift toward scar and immune-rich ground. Holdouts showed marks of escape routes, a hint for next plans.

Catalog record

CREATORShiyue Wan, Shiqi Hu, Yilv Yan, Fenghuan Sun, Dongliang Bian, Jie Luo, Dong Xie, Wenxin He, Liang Duan, Yuming Zhu, Nan Song, Ming Liu, Hongcheng Liu, Gening Jiang, Peng Zhang
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE51 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13542703

Browse the full library · About the Tower of Babel